Patients with prostate cancer experience a steady decline in quality of life (QOL) over the 12-month period before death

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.306, 2001-01, pp. : 11-11

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Measuring quality of life (QOL) in paediatric patients is a challenge

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 250, 2000-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

Health-Related Quality-of-Life Assessments in Patients with Advanced Cancer of the Prostate

By Adolfsson J.  

PharmacoEconomics, Vol. 21, Iss. 4, 2003-01 ,pp. : 241-247

Adis International

Access to resources Recommend Favorite

The MIDAS is a `highly reliable' tool for measuring quality of life (QOL) in patients

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 388, 2002-01 ,pp. : 10-10

Adis International

Access to resources Recommend Favorite

Quality of Life and Economic Considerations in the Management of Prostate Cancer

By Turini M.   Redaelli A.   Gramegna P.   Radice D.  

PharmacoEconomics, Vol. 21, Iss. 8, 2003-01 ,pp. : 527-541

Adis International

Access to resources Recommend Favorite

A Review of Quality-of-Life Evaluations in Prostate Cancer

By Sommers S.D.  

PharmacoEconomics, Vol. 16, Iss. 2, 1999-08 ,pp. : 127-140

Adis International

Access to resources Recommend Favorite